Clinical Evaluation of Piperacillin

Publisher Website
Google Scholar
Abstract
Patients (28) with aerobic (7), anaerobic (7) and mixed (14) infections were treated with i.v. piperacillin for an average duration of 14 days. All bacterial isolates tested in this study were susceptible to piperacillin .ltoreq. 128 .mu.g/ml. Patients (27) were treated with 20 g of piperacillin/day in 4 divided doses. One patient with renal failure received only 8 g/day; 26 patients were treated with piperacillin and 2 with Staphylococcus aureus infection received gentamicin in addition The peak serum levels were 266 .mu.g/ml at 1 h and the trough 16 .mu.g/ml at 5 h. In all, 26 patients (93%) were cured, 1 had recurrence, and 1 failed. Adverse effects were pruritus in 2 patients, transient elevation of lactute dehydrogenase in one and transient eosinophilia in another. In this preliminary study, piperacillin was safe and effective in the treatment of clinical infections.

This publication has 1 reference indexed in Scilit: